Literature DB >> 7488460

Reductions in muscle sympathetic nerve activity after long-term metoprolol for dilated cardiomyopathy: preliminary observations.

M A Rahman1, K Hara, P A Daly, E D Wigle, J S Floras.   

Abstract

OBJECTIVE: To determine whether efferent muscle sympathetic nerve activity diminishes in subjects with dilated cardiomyopathy who improve after long term treatment with metoprolol.
METHODS: Microneurographic, echocardiographic, plethysmographic, and neurohumoral data were obtained immediately before and 20 months after the addition of beta blockade in seven subjects with idiopathic dilated cardiomyopathy with clinical deterioration despite conventional treatment.
RESULTS: Six subjects (three men, three women, aged 24-62 years) were restudied after a mean (SEM) of 20 (2.4) months treatment with metoprolol (45.8 (2.6) mg/d). Long term treatment was associated with decreases in left ventricular end diastolic and end systolic diameter (P < 0.005), left ventricular mass index (P < 0.05), and atrial natriuretic factor (P < 0.05), and increases in fractional shortening (P < 0.05) and mean blood pressure (P < 0.05). There was a 50% reduction in peroneal muscle sympathetic nerve activity (from 49.2 (10.1) to 24.5 (4.7) bursts/min; (P < 0.005) and a 62% decrease in calf vascular resistance (from 56.2 (4.4) to 21.2 (5.7) units; P < 0.005). This reduction in pulse synchronous nerve activity was not simply a function of bradycardia (heart rate fell from 94.2 (4.6) to 62.8 (5.7) beats/min; P < 0.005) since muscle sympathetic burst incidence also decreased (from 51 (8.7) to 37.5 (5.2) bursts/100 heart beats; P < 0.05). Similar haemodynamic improvement was observed in the seventh subject, who was switched to sotalol 200 mg/d and restudied after 20 months, but burst frequency was 50% higher and calf vascular resistance 93% higher.
CONCLUSIONS: Muscle sympathetic nerve activity and calf vascular resistance decrease in patients with dilated cardiomyopathy who improve after long term treatment with metoprolol. Inhibition of central sympathetic outflow may be one mechanism by which metoprolol benefits such subjects.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7488460      PMCID: PMC484052          DOI: 10.1136/hrt.74.4.431

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  25 in total

1.  Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method.

Authors:  R B Devereux; N Reichek
Journal:  Circulation       Date:  1977-04       Impact factor: 29.690

2.  Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure.

Authors:  M R Bristow; R Ginsburg; V Umans; M Fowler; W Minobe; R Rasmussen; P Zera; R Menlove; P Shah; S Jamieson
Journal:  Circ Res       Date:  1986-09       Impact factor: 17.367

3.  The variability of muscle nerve sympathetic activity in resting recumbent man.

Authors:  G Sundlöf; B G Wallin
Journal:  J Physiol       Date:  1977-11       Impact factor: 5.182

4.  Beta 1- and beta 2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium.

Authors:  M R Bristow; R E Hershberger; J D Port; W Minobe; R Rasmussen
Journal:  Mol Pharmacol       Date:  1989-03       Impact factor: 4.436

5.  Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial.

Authors:  R S Engelmeier; J B O'Connell; R Walsh; N Rad; P J Scanlon; R M Gunnar
Journal:  Circulation       Date:  1985-09       Impact factor: 29.690

6.  Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure.

Authors:  J N Cohn; T B Levine; M T Olivari; V Garberg; D Lura; G S Francis; A B Simon; T Rector
Journal:  N Engl J Med       Date:  1984-09-27       Impact factor: 91.245

7.  Sympathetic outflow to muscles during treatment of hypertension with metoprolol.

Authors:  B G Wallin; G Sundlöf; E Strömgren; H Aberg
Journal:  Hypertension       Date:  1984 Jul-Aug       Impact factor: 10.190

8.  Oral beta-adrenergic blockade with metoprolol in chronic severe dilated cardiomyopathy.

Authors:  P J Currie; M J Kelly; A McKenzie; R W Harper; Y L Lim; J Federman; S T Anderson; A Pitt
Journal:  J Am Coll Cardiol       Date:  1984-01       Impact factor: 24.094

9.  Failure of plasma norepinephrine to consistently reflect sympathetic activity in humans.

Authors:  J Floras; J Vann Jones; M O Hassan; B A Osikowska; P S Sever; P Sleight
Journal:  Hypertension       Date:  1986-08       Impact factor: 10.190

10.  Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity.

Authors:  G J Hasking; M D Esler; G L Jennings; D Burton; J A Johns; P I Korner
Journal:  Circulation       Date:  1986-04       Impact factor: 29.690

View more
  2 in total

1.  Effects of carvedilol therapy on QT-interval dispersion in congestive heart failure: is there a difference in the elderly?

Authors:  Ricardo Mourilhe Rocha; Guilherme Vienna Silva; Emerson C Perin; André Regazzi Gerk; Ellas Pimentel Gouvea; Valéria Martin Soares Santos; Francisco Manes Albanesi Filho; Denilson Campos de Albuquerque
Journal:  Tex Heart Inst J       Date:  2003

Review 2.  Effects of beta-blockers on neurohormonal activation in patients with congestive heart failure.

Authors:  D Baran; E M Horn; K Hryniewicz; S D Katz
Journal:  Drugs       Date:  2000-11       Impact factor: 11.431

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.